2.50
Hdl Handle:
http://hdl.handle.net/10541/74033
Title:
New therapeutic agents in ovarian cancer.
Authors:
Collinson, Fiona J; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
PURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
Affiliation:
University of Leeds, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uk
Citation:
New therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.
Journal:
Current Opinion in Obstetrics & Gynecology
Issue Date:
Feb-2009
URI:
http://hdl.handle.net/10541/74033
DOI:
10.1097/GCO.0b013e32831ffe71
PubMed ID:
19125003
Type:
Article; Book
Language:
en
ISSN:
1473-656X
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorCollinson, Fiona J-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-16T09:11:06Z-
dc.date.available2009-07-16T09:11:06Z-
dc.date.issued2009-02-
dc.identifier.citationNew therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.en
dc.identifier.issn1473-656X-
dc.identifier.pmid19125003-
dc.identifier.doi10.1097/GCO.0b013e32831ffe71-
dc.identifier.urihttp://hdl.handle.net/10541/74033-
dc.description.abstractPURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectTargeted Therapiesen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarboplatin-
dc.subject.meshDrug Administration Routes-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPaclitaxel-
dc.subject.meshPoly Adenosine Diphosphate Ribose-
dc.subject.meshProtein Kinase Inhibitors-
dc.subject.meshProteins-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.titleNew therapeutic agents in ovarian cancer.en
dc.typeArticleen
dc.typeBooken
dc.contributor.departmentUniversity of Leeds, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uken
dc.identifier.journalCurrent Opinion in Obstetrics & Gynecologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.